Behcet Disease Clinical Features and Management in a Brazilian Tertiary Hospital

被引:20
作者
Diniz Oliveira, Ana Cecilia [1 ]
Pirozzi Buosi, Ana Leticia [1 ]
Dutra, Livia Almeida [2 ]
Silva de Souza, Alexandre Wagner [1 ]
机构
[1] Univ Fed Sao Paulo, Div Rheumatol, Dept Med, BR-04023900 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Neurol & Neurosurg, BR-04023900 Sao Paulo, Brazil
关键词
Behcet syndrome; uveitis; colchicine; immunosuppressive agents; DOSE WEEKLY METHOTREXATE; NERVOUS-SYSTEM SYMPTOMS; DOUBLE-BLIND; CYCLOSPORINE-A; MANIFESTATIONS; RECOMMENDATIONS; POPULATION; PENICILLIN; THERAPY; UVEITIS;
D O I
10.1097/RHU.0b013e31823a46ed
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Behcet disease (BD) is prevalent in Central and East Asia and in the Eastern Mediterranean area where most studies have been performed. Few studies have evaluated patients with BD in Brazil. Objectives: The objective of the study was to describe clinical manifestations of BD and their therapy in a single center in Brazil. Methods: Sixty patients who met the International Study Group Criteria for BD and were under follow-up at the Vasculitis Unit of the Universidade Federal de Sao Paulo were evaluated in a retrospective observational study. Results: Mean age at study was 40.0 (SD, 10.7) years, and the femalemale ratio was 1.2:1.0. The frequency of disease manifestations was as follows: oral ulcers, 100%; genital ulcers, 93.3%; ocular manifestations, 63.3%; arthritis, 46.7%; cutaneous lesions, 71.7%; positive pathergy test, 22.7%; neurologic involvement, 28.3%; thrombosis, 13.3%; and gastrointestinal involvement, 3.3%. Arthritis and erythema nodosum were more prevalent among women, whereas papulopustular lesions were more common in men. The frequency of each treatment modality was as follows: colchicine, 78.3%; thalidomide, 26.7%; colchicine and penicillin, 21.7%; dapsone, 8.3%; and pentoxyphyline, 8.3%. These treatments were mainly used for mucocutaneous manifestations. Immunosuppressive drugs were prescribed for 70% of the patients, including azathioprine (35.0%), cyclophosphamide (28.3%), cyclosporin A (21.7%), methotrexate (18.3%), and chlorambucil (6.7%). Infliximab was used in 5.0% of refractory patients. No differences were observed between sexes related to severe manifestations of BD. Conclusions: Although reported elsewhere, Brazilian men with BD did not have a worse prognosis. Women had a higher frequency of arthritis manifestations.
引用
收藏
页码:416 / 420
页数:5
相关论文
共 44 条
  • [1] Aguiar SB, 1997, REV BRAS REUMATOL, V37, P66
  • [2] Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation
    Ahn, Joong Kyong
    Lee, You Sun
    Jeon, Chan Hong
    Koh, Eun-Mi
    Cha, Hoon-Suk
    [J]. CLINICAL RHEUMATOLOGY, 2008, 27 (02) : 201 - 205
  • [3] Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter study
    Bang, D
    Lee, JH
    Lee, ES
    Lee, S
    Choi, JS
    Kim, YK
    Cho, BK
    Koh, JK
    Won, YH
    Kim, NI
    Park, SD
    Ahn, HJ
    Lee, YW
    Wang, HY
    Lee, WW
    Eun, HC
    Song, ES
    Lee, SW
    Lee, CW
    Lee, CJ
    Park, JH
    Song, YW
    Kim, ST
    Kim, CY
    Park, JK
    Kwon, KS
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2001, 16 (05) : 615 - 618
  • [4] BARRA C, 1991, JPN J OPHTHALMOL, V35, P339
  • [5] Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease
    Calguneri, M
    Ertenli, I
    Kiraz, S
    Erman, M
    Celik, I
    [J]. DERMATOLOGY, 1996, 192 (02) : 125 - 128
  • [6] The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease - A randomized clinical trial
    Calguneri, M
    Kiraz, S
    Ertenli, I
    Benekli, M
    Karaarslan, Y
    Celik, I
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (12): : 2062 - 2065
  • [7] THE PATHERGY TEST AND BEHCETS SYNDROME IN BRITAIN
    DAVIES, PG
    FORDHAM, JN
    KIRWAN, JR
    BARNES, CG
    DINNING, WJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1984, 43 (01) : 70 - 73
  • [8] Cerebral venous thrombosis in Behcet's disease: a systematic review
    de Sousa, D. Aguiar
    Mestre, T.
    Ferro, J. M.
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 (05) : 719 - 727
  • [9] Ferraz MB, 1995, BR J RHEUMATOL, V34, P392
  • [10] Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial
    Hamuryudan, V
    Mat, C
    Saip, S
    Ozyazgan, Y
    Siva, A
    Yurdakul, S
    Zwingenberger, K
    Yazici, H
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (06) : 443 - +